Pain Relief vs Addiction: Will Vertex’s non-opioid (hopefully nonaddictive) Suzetrigine/VX-548 be FDA-approved in 2024?
Basic
5
Ṁ87Jan 5
31%
chance
1D
1W
1M
ALL
Resolution source:
From Wikipedia:
Vertex announced in January 2024 that VX-548 successfully met several enpoints in its Phase III trials. The drug relieved moderate to severe post-surgical pain. Vertex hopes the drug, which operates on peripheral nerves, will avoid the addictive potential of opioids. There are many other small molecule sodium channel blocker candidates.
Independence:
I will not take positions related to this question on any market sites.
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Sort by:
Per https://news.vrtx.com/news-releases/news-release-details/vertex-announces-fda-acceptance-new-drug-application-suzetrigine, Vertex expects FDA action in January 2025.
@nonnihil Thank you for the heads up! Please let me know if this schedule gets accelerated or delayed.
Related questions
Related questions
Will Suzetrigine/VX-548 (non-opioid painkiller) be prescribed to >500k patients in 2025?
50% chance
Will the FDA approve a drug to prevent migraine headaches by 2025?
66% chance
Will a drug to be used by most healthy adults be approved by 2043 year end?
66% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
35% chance
Will the FDA approve MDMA as a treatment for PTSD by the end of 2024?
3% chance
Will Scott Alexander endorse a Delta-Opioid-Agonist antidepressant before 2029?
58% chance
Will a drug that didn't go through human clinical trials be approved by 2034?
29% chance
Will an AI-designed drug get FDA approval by the end of 2025?
30% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
64% chance
Will the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
71% chance